Kodiak Sciences stock gains 8.08 percent to EUR 84.54

Published on 10/20/2026 at 18:53 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Market value reached USD 6.0 billion on October 20, 2026. Kodiak Sciences stock costs EUR 84.54 on October 20, 2026, up 8.08 percent versus Frankfurt close.

Price and clinical milestones

Kodiak Sciences stock stood 8.08 percent above the Frankfurt close on October 20, 2026.
Kodiak reported three late-stage programs for AAO 2026 on October 7, 2026.
Kodiak Sciences stock costs EUR 84.54 at Lang & Schwarz on October 20, 2026, 8.08 percent above the Frankfurt close of October 16, 2026.
PEAK topline data are expected in December 2026.

KOD, US50015M1099, Illustration mit AI erstellt.

Kodiak Sciences (ISIN US50015M1099) traded at EUR 84.54 at Lang & Schwarz on October 20, 2026 at 6:43 p.m. CEST, 8.08 percent above the Frankfurt close of October 16, 2026 at EUR 78.22. The latest company material puts the focus on clinical milestones rather than commercial revenue.

On October 7, 2026, Kodiak Sciences said it would present data from all three late-stage programs at the American Academy of Ophthalmology meeting. The release said the Phase 3 DAYBREAK study met its primary endpoint for both Zenkuda and tabirafusp-ted, with non-inferior vision gains versus aflibercept at Year 1.

Clinical milestones shape the timeline

The company said PEAK topline data for KSI-101 are expected in December 2026, while PEAK plus PINNACLE data are expected in the second quarter of 2027. That schedule gives investors two dated development markers beyond the September 28, 2026 DAYBREAK topline announcement.

Price position after the move

On Nasdaq, Kodiak was at USD 95.52 at 12:51 p.m. EDT on October 20, 2026, with 402,749 shares traded. The quote was 8.15 percent below the USD 104.00 52-week high and above the USD 15.83 52-week low.

The USD 6.0 billion market capitalization and the 52-week range place the biotechnology company near the upper end of its annual trading band. The Nasdaq quote had risen USD 4.17, or 4.56 percent, from its prior session level of USD 91.35 at that timestamp.

Valuation and upcoming dates

Gekko lists November 12, 2026 as Kodiak's next earnings date and cites an expected adjusted loss of USD 1.06 per share. The company's second-quarter 2026 net loss was USD 65.64 million, while operating cash flow was negative USD 46.24 million for the same period.

Comparison with peers

KOD (Nasdaq, USD): up 4.56 percent, market capitalization USD 6.0 billion.

Regeneron Pharmaceuticals (Nasdaq, USD): up 1.39 percent, P/E 19.61, market capitalization USD 81.6 billion.

Novartis (NYSE, USD): up 2.07 percent, P/E 23.38, market capitalization USD 291.4 billion.

Nasdaq position and next report

Kodiak's euro quote stood at EUR 84.54 at Lang & Schwarz on October 20, 2026 at 6:43 p.m. CEST, 8.08 percent above the Frankfurt close of October 16, 2026 at EUR 78.22. The next scheduled earnings date listed by Gekko is November 12, 2026.

The further course of trading is shown by the continuously updated real-time quote of Kodiak Sciences stock.